Effects of progestogens on the postmenopausal breast

Area of Science:

• Endocrinology and reproductive science
• Oncology
• Molecular biology

Background:

• The use of hormone replacement therapy (HRT) in postmenopausal women is debated due to potential breast cancer risks associated with combined estrogen-progestin therapy.
• Despite decades of research, the precise effects of progesterone and synthetic progestins on breast tissue physiology remain controversial.
• Existing epidemiological data on HRT and breast cancer risk are inconsistent, partly due to variations in study designs and steroid formulations.

Discussion:

• The physiological rise of endogenous progesterone during the luteal phase correlates with decreased breast epithelial cell proliferation.
• Different synthetic progestins, dosages, and administration routes (oral vs. transdermal) yield varying effects on breast tissue mitogenesis.
• The specific estrogen (estrone vs. estradiol) accumulated in breast tissue may influence the impact of progestogen therapy.

Key Insights:

• Hormone replacement therapy (HRT) combining oral conjugated equine estrogens with medroxyprogesterone acetate may increase mitogenic activity more than transdermal estradiol with progesterone.
• It is biologically plausible that progesterone counteracts the proliferative effects of estradiol in postmenopausal breast tissue.
• Classifying all progestogens similarly is misleading; their chemical structure and interaction with specific estrogens are critical.

Outlook:

• Further research is needed to differentiate the effects of various progestogens and estrogen formulations on breast cancer risk.
• Clarifying the role of endogenous progesterone in breast health may inform safer HRT strategies.
• Personalized HRT approaches considering individual hormonal profiles and specific steroid combinations are warranted.